These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25436337)

  • 21. Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.
    Fendler WP; Lechner H; Todica A; Paprottka KJ; Paprottka PM; Jakobs TF; Michl M; Bartenstein P; Lehner S; Haug AR
    J Nucl Med; 2016 Apr; 57(4):517-23. PubMed ID: 26742710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
    Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
    Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
    Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
    J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
    Saxena A; Kapoor J; Meteling B; Morris DL; Bester L
    Ann Surg Oncol; 2014 Apr; 21(4):1296-303. PubMed ID: 24337647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y; Naghavi AO; Ahmed KA; Venkat PS; Kim Y; Kis B; Choi J; Biebel B; Sweeney J; Anaya DA; Kim R; Malafa M; Frakes JM; Hoffe SE; El-Haddad G
    World J Gastroenterol; 2016 Dec; 22(47):10406-10414. PubMed ID: 28058021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
    Mouli S; Memon K; Baker T; Benson AB; Mulcahy MF; Gupta R; Ryu RK; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2013 Aug; 24(8):1227-34. PubMed ID: 23602420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
    Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
    J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival.
    Dunfee BL; Riaz A; Lewandowski RJ; Ibrahim S; Mulcahy MF; Ryu RK; Atassi B; Sato KT; Newman S; Omary RA; Benson A; Salem R
    J Vasc Interv Radiol; 2010 Jan; 21(1):90-5. PubMed ID: 19939705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients.
    Saxena A; Meteling B; Kapoor J; Golani S; Morris DL; Bester L
    Ann Surg Oncol; 2015 Mar; 22(3):794-802. PubMed ID: 25323474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serious hepatic complications of selective internal radiation therapy with yttrium-90 microsphere radioembolization for unresectable liver tumors.
    Kuo JC; Tazbirkova A; Allen R; Kosmider S; Gibbs P; Yip D
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):266-72. PubMed ID: 25135200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases.
    Cao CQ; Yan TD; Bester L; Liauw W; Morris DL
    Br J Surg; 2010 Apr; 97(4):537-43. PubMed ID: 20205229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
    Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
    J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intra-arterial radioembolization of breast cancer liver metastases: a structured review.
    Smits ML; Prince JF; Rosenbaum CE; van den Hoven AF; Nijsen JF; Zonnenberg BA; Seinstra BA; Lam MG; van den Bosch MA
    Eur J Pharmacol; 2013 Jun; 709(1-3):37-42. PubMed ID: 23545356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
    Kim AY; Frantz S; Brower J; Akhter N
    J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.